Commentary Open Access
Volume 5 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.4.037
The Role of the General Practitioner in Vaccination against COVID-19
Jose Luis Turabian1,*
- 1Specialist in Family and Community Medicine, Health Center Santa Maria de Benquerencia, Regional Health Service of Castilla la Mancha (SESCAM), Toledo, Spain
Corresponding Author
Jose Luis Turabian, jturabianf@hotmail.com
Received Date: November 08, 2022
Accepted Date: December 16, 2022
Turabian JL. The Role of the General Practitioner in Vaccination against COVID-19. Arch Pharmacol Ther. 2023;5(1):5-7.
Copyright: © 2023 Turabian JL. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
COVID-19, Adverse drug events, COVID-19 vaccine, General practice
Recommended Articles
How Well Do Hemodialysis Patients Respond to the BNT162b2 mRNA COVID-19 Vaccine?
In January 2020, the World Health Organization (WHO) classified COVID-19 to be a Public Health Emergency of International Concern and declared it a pandemic on March 11, 2020 [1]. Over one hundred and eighty-five million people have been infected by SARS-CoV-2 and roughly four million have died worldwide so far
COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer
Since the declaration of COVID-19 as a pandemic in March 2020 [1], there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths [2].
COVID-19 and the Health of Illicit Substance Users: Preliminary Analysis from Illicit Drug Transaction Data
While much attention has been given to how COVID-19 patients are treated (or fail to be treated), the impact of the pandemic on illicit drug users remains largely undiscussed
COVID-19 Rapid Diagnostic Test Results and their Associations with Certain Factors Among the Residents of Balochistan
This paper analyses any possible association of various factors like gender, last COVID-19 PCR test results, BCG Vaccination, Seasonal Flu vaccination, occupation and confirmed case contact history with COVID-19 RDT results of the participants.
Relative COVID-19 Vaccine Booster Effectiveness and ClinicalEpidemiological Characteristics Before and After 29 Days of Shot
Background: When the highest vaccine COVID-19 booster effectiveness (VBE) is obtained is not clearly known. Objective: To compare the cases of COVID-19 in booster vaccinated people with a time of <29 days vs. ≥ 29 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective case series study of adult patients with COVID-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave.